Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Kaufman

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|August 19, 2020
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabineShayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, et al.
Breast Cancer (Dove Medical Press)|November 29, 2023
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate TherapyRavi K Goyal, Jingchuan Zhang, Keith L Davis, et al.
Clinical Breast Cancer|March 20, 2010
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerChris Twelves, Javier Cortes, Linda T Vahdat, et al.
Breast Cancer Research and Treatment|February 4, 2024
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancerRavi K Goyal, Jingchuan Zhang, Keith L Davis, et al.
Breast Cancer Research and Treatment|April 26, 2008
Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effectiveMarc Schegerin, Anna N A Tosteson, Peter A Kaufman, et al.
Breast Cancer Research and Treatment|November 9, 2014
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesChris Twelves, Javier Cortes, Linda Vahdat, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|October 23, 2013
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatmentAlicia A Petryk, Andrew J Giustini, Rachel E Gottesman, et al.
IEEE Transactions on Medical Imaging|May 8, 2012
Fast 3-d tomographic microwave imaging for breast cancer detectionTomasz M Grzegorczyk, Paul M Meaney, Peter A Kaufman, et al.
Clinical Breast Cancer|June 14, 2018
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast CancerKaren A Cadoo, Peter A Kaufman, Andrew D Seidman, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 19, 2025
Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed RegimensCarey Anders, Edward Neuberger, Karen Bartley, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|August 19, 2020
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabineShayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, et al.
Breast Cancer (Dove Medical Press)|November 29, 2023
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate TherapyRavi K Goyal, Jingchuan Zhang, Keith L Davis, et al.
Clinical Breast Cancer|March 20, 2010
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerChris Twelves, Javier Cortes, Linda T Vahdat, et al.
Breast Cancer Research and Treatment|February 4, 2024
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancerRavi K Goyal, Jingchuan Zhang, Keith L Davis, et al.
Breast Cancer Research and Treatment|April 26, 2008
Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effectiveMarc Schegerin, Anna N A Tosteson, Peter A Kaufman, et al.
Breast Cancer Research and Treatment|November 9, 2014
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesChris Twelves, Javier Cortes, Linda Vahdat, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|October 23, 2013
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatmentAlicia A Petryk, Andrew J Giustini, Rachel E Gottesman, et al.
IEEE Transactions on Medical Imaging|May 8, 2012
Fast 3-d tomographic microwave imaging for breast cancer detectionTomasz M Grzegorczyk, Paul M Meaney, Peter A Kaufman, et al.
Clinical Breast Cancer|June 14, 2018
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast CancerKaren A Cadoo, Peter A Kaufman, Andrew D Seidman, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 19, 2025
Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed RegimensCarey Anders, Edward Neuberger, Karen Bartley, et al.
Pageof 10